PTAB challenges

Based on a review of the patent's litigation history and available records, here is an analysis of the AIA trial proceedings for US Patent 5,412,730.

Proceedings overview

There has been one AIA trial proceeding filed against US Patent 5,412,730, a Covered Business Method (CBM) review which was terminated due to a settlement between the parties before an institution decision was made. Because the proceeding did not result in a final written decision, no claims have been invalidated or sustained by the PTAB, which provides a defendant with a clean slate to pursue a validity challenge at the PTAB without prior art estoppel from this case.

CBM2014-00007 — Callidus Software, Inc. v. TQP Development, LLC

• Type: Covered Business Method (CBM) Review
• Filed: 2013-10-11
• Status: Terminated. The proceeding was ended at the joint request of the petitioner and patent owner, indicating a settlement was reached.
• Judge panel: The case was terminated before a panel was publicly assigned to render an institution or final decision.
• Petition grounds: The petition challenged claims 1-9 of US Patent 5,412,730. The specific statutory grounds and prior art references are detailed in the petition document filed with the PTAB. CBM petitions typically allege that the challenged claims are directed to a covered business method and are invalid under sections 101, 102, 103, and/or 112.
• Institution decision: None. The proceeding was terminated on 2013-12-03, before an institution decision was rendered. Therefore, the PTAB never determined whether there was a reasonable likelihood that the petitioner would prevail on its challenges.
• Final Written Decision: None. As the case was terminated pre-institution, no trial was conducted and no Final Written Decision (FWD) was issued.
• Settlement / termination: The parties filed a joint motion to terminate the proceeding on 2013-12-02, stating they had resolved the matter pursuant to a settlement agreement. The PTAB granted the motion and terminated the proceeding the following day. The specific terms of the settlement are confidential. This termination also resolved the parallel district court case, TQP Development, LLC v. Callidus Software, Inc., No. 2:12-cv-00799 (E.D. Tex.).
• Appeal: Not applicable. There was no Final Written Decision to appeal to the U.S. Court of Appeals for the Federal Circuit.
• Defensive value: This proceeding provides minimal direct defensive value, as it did not invalidate any claims. However, its history is strategically significant. Because it was terminated without a Final Written Decision, no statutory estoppel under 35 U.S.C. § 325(e) applies to the petitioner (Callidus Software) or any other party. This means that a future defendant is not barred from filing a new IPR or PGR and raising the same invalidity grounds or prior art. The fact that the patent owner settled rather than face a validity challenge could signal a risk tolerance that might be exploited in future negotiations.

Strategic summary

The validity of US Patent 5,412,730 has not been substantively tested before the Patent Trial and Appeal Board. The single CBM review was terminated at the preliminary stage, leaving all claims—independent claims 1, 6, 8, and 9, and their dependents—officially UNTESTED by the PTAB. Consequently, no claims are currently CANCELED or SUSTAINED from an AIA trial.

The estoppel landscape is entirely open for a newly accused infringer. Under 35 U.S.C. § 315(e)(2) (for IPRs) and § 325(e)(2) (for CBMs/PGRs), estoppel only attaches to a petitioner after a Final Written Decision is issued. Since CBM2014-00007 did not result in an FWD, a new defendant can challenge any claim of the '730 patent at the PTAB on any ground that could have been raised. The pattern of a single defendant filing a CBM that quickly results in a global settlement of district court litigation is common; it demonstrates the leverage that AIA trials can provide for resolving disputes efficiently. The absence of further PTAB challenges, especially from defensive aggregators like Unified Patents, is notable given the patent's extensive assertion history, perhaps indicating that many defendants preferred to settle for nuisance value rather than fund a full invalidity challenge.

Recommended next steps

For a defendant currently facing a demand letter citing US Patent 5,412,730:

• Recognize that no claims of this patent have been invalidated or "hardened" by the PTAB. The patent's validity remains an open question for an administrative challenge.
• Given the patent's 1992 priority date, it is only eligible for Inter Partes Review (IPR), not Post-Grant Review (PGR). A new IPR petition would be the appropriate vehicle for a validity challenge at the PTAB.
• The absence of PTAB activity is a significant data point. While hundreds of companies have been sued on this patent, only one appears to have initiated a PTAB challenge, which was quickly settled. A potential defendant should conduct a thorough prior art search to assess the viability of a new IPR, as this path remains fully available and unencumbered by estoppel from prior proceedings.